HomeCompareEIGRQ vs MCD

EIGRQ vs MCD: Dividend Comparison 2026

EIGRQ yields 23.53% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGRQ wins by $11.9K in total portfolio value
10 years
EIGRQ
EIGRQ
● Live price
23.53%
Share price
$8.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.5K
Annual income
$9,663.72
Full EIGRQ calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — EIGRQ vs MCD

📍 EIGRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRQMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGRQ + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGRQ pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGRQ
Annual income on $10K today (after 15% tax)
$2,000.00/yr
After 10yr DRIP, annual income (after tax)
$8,214.16/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $14,079.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGRQ + MCD for your $10,000?

EIGRQ: 50%MCD: 50%
100% MCD50/50100% EIGRQ
Portfolio after 10yr
$84.5K
Annual income
$17,945.71/yr
Blended yield
21.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

EIGRQ
No analyst data
Altman Z
-24.3
Piotroski
4/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGRQ buys
0
MCD buys
0
No recent congressional trades found for EIGRQ or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRQMCD
Forward yield23.53%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$90.5K$78.5K
Annual income after 10y$9,663.72$26,227.70
Total dividends collected$55.7K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: EIGRQ vs MCD ($10,000, DRIP)

YearEIGRQ PortfolioEIGRQ Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$13,053$2,352.94$10,815$334.85+$2.2KEIGRQ
2$16,837$2,870.36$11,826$491.71+$5.0KEIGRQ
3$21,476$3,460.26$13,123$730.06+$8.4KEIGRQ
4$27,104$4,124.87$14,853$1,100.07+$12.3KEIGRQ
5$33,867$4,865.30$17,257$1,690.61+$16.6KEIGRQ
6$41,919$5,681.51$20,752$2,667.01+$21.2KEIGRQ
7$51,425$6,572.30$26,103$4,354.83+$25.3KEIGRQ
8$62,561$7,535.33$34,794$7,437.78+$27.8KEIGRQ
9$75,507$8,567.24$49,926$13,461.60+$25.6KEIGRQ
10$90,456$9,663.72$78,550$26,227.70+$11.9KEIGRQ

EIGRQ vs MCD: Complete Analysis 2026

EIGRQStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Full EIGRQ Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this EIGRQ vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGRQ vs SCHDEIGRQ vs JEPIEIGRQ vs OEIGRQ vs KOEIGRQ vs MAINEIGRQ vs YUMEIGRQ vs QSREIGRQ vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.